G. Kurteva

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

Florian Lordick, Yoon‐Koo Kang, Hyun Cheol Chung et al. · The Lancet Oncology · 2013 · 830 citations · Full text

Gastrointestinal Oncology, Advanced Gastric Cancer, Open-label Phase 3 +9

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: ALTERNATIVE

Stephen Johnston, Roberto Hegg, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2017 · 166 citations · Full text

Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)

Paulo M. Hoff, Andreas Hochhaus, Bernhard C. Pestalozzi et al. · Journal of Clinical Oncology · 2012 · 152 citations · Full text

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE

Stephen Johnston, Roberto Hegg, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2020 · 124 citations

Breast Oncology, Cancer Management, Pharmacotherapy +19

Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx ^® ): a placebo-controlled randomised phase II study (PLIANT)

Bengt Glimelius, Nebojša Manojlović, Per Pfeiffer et al. · Acta Oncologica · 2017 · 83 citations · Full text